DarioHealth Corp. (NASDAQ:DRIO) Given Consensus Rating of “Hold” by Analysts

DarioHealth Corp. (NASDAQ:DRIO) has earned an average rating of “Hold” from the five analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $32.00.

A number of equities analysts have recently commented on DRIO shares. Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Stifel Nicolaus set a $16.00 price target on DarioHealth in a research report on Friday, November 14th. Cowen reiterated a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th.

DarioHealth Stock Down 5.7%

Shares of NASDAQ:DRIO opened at $12.16 on Friday. The company has a market cap of $82.20 million, a price-to-earnings ratio of -1.09 and a beta of 1.05. DarioHealth has a 12 month low of $5.93 and a 12 month high of $27.60. The company has a current ratio of 4.55, a quick ratio of 4.02 and a debt-to-equity ratio of 0.41. The company has a 50-day moving average price of $12.06 and a 200 day moving average price of $12.14.

Institutional Investors Weigh In On DarioHealth

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd grew its holdings in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the period. XTX Topco Ltd owned about 0.14% of DarioHealth worth $42,000 as of its most recent filing with the Securities & Exchange Commission. 33.39% of the stock is currently owned by institutional investors.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.